Welcome to our dedicated page for Amedisys news (Ticker: AMED), a resource for investors and traders seeking the latest updates and insights on Amedisys stock.
Amedisys Inc. (NASDAQ: AMED) is a leading healthcare services company in the United States, specializing in delivering personalized home health, hospice, and high-acuity care services. Headquartered in Baton Rouge, LA, with an executive office in Nashville, TN, the company employs around 18,700 staff across 520 care centers in 37 states and the District of Columbia. Founded in 1982, Amedisys is dedicated to providing quality, clinically-distinctive care to more than 469,000 patients annually, with over 10.6 million visits each year.
Amedisys operates across four key segments: Home Health, Hospice, High Acuity Care, and Personal Care. The Home Health segment offers skilled nursing, therapy, and aid services directly in patients' homes, while the Hospice segment provides end-of-life care to terminally ill patients. The High Acuity Care segment delivers critical inpatient care elements at home, and the Personal Care segment, which was divested in March 2023, offered assistance with daily living activities.
Amedisys's commitment to high-quality care is underpinned by its comprehensive coordination with healthcare providers and personalized care plans tailored to each patient's unique needs. With a strong network involving more than 3,000 hospitals and 110,000 physicians nationwide, Amedisys is a trusted partner in post-acute care.
Recent notable achievements include a merger agreement with UnitedHealth Group, aimed at enhancing patient care through integrated services. Financially, Amedisys reported a net service revenue increase to $571.4 million for Q1 2024, reflecting a robust service demand despite divesting the Personal Care segment.
Additionally, Amedisys is actively involved in advancing healthcare technology. The company has partnered with Patient Choice Laboratories to incorporate advanced molecular testing, enhancing infection diagnosis and patient outcomes. This innovation underscores Amedisys’s commitment to leveraging cutting-edge technology to improve patient care.
For stakeholders, Amedisys remains a prominent figure in the home healthcare industry, constantly adapting and growing to meet the increasing needs of its patient population. The company's strategic partnerships and advancements in healthcare technology position it well for sustained growth and improved patient outcomes.
Amedisys, Inc. (NASDAQ: AMED), a premier home health and hospice service provider, announced key presentations by its CEO Paul Kusserow and Acting COO Scott Ginn. They will speak at Oppenheimer’s 33rd Annual Healthcare Conference on March 14 at 10:00 a.m. ET and at the Barclays Global Healthcare Conference on March 15 at 8:50 a.m. ET. Investors can access the live webcast via the company’s investor website. Amedisys offers personalized care services to over 465,000 patients annually through its 532 centers across 37 states. The company has relationships with over 102,000 physicians and more than 3,000 hospitals nationwide.
Amedisys has announced a strategic move to divest its Personal Care division to HouseWorks, enhancing its care coordination network. This partnership aims to provide seamless personal care services in several states, leveraging HouseWorks' footprint and eCaring's comprehensive software solutions. The CEO of Amedisys stated that this divestiture allows the company to focus on its core services in Home Health, Hospice, and High Acuity Care. The deal is expected to close in Q2 2023, demonstrating Amedisys' commitment to improving patient care delivery while maintaining a robust personal care network.
Amedisys, a provider of home health and hospice care, has announced a new agreement with BlueCross BlueShield of Tennessee to deliver palliative care at home for members in Middle Tennessee. This program focuses on patients with chronic or advanced illnesses, allowing them to receive in-person or telehealth care without additional costs. The initiative aligns with Amedisys' strategy to develop risk-based models with payers, enhancing patient quality of life while reducing hospitalizations. The company aims to expand its reach and improve care delivery in patients' homes.
Amedisys, Inc. (NASDAQ: AMED) reported its financial results for Q4 and the fiscal year ended December 31, 2022. Net service revenue increased by $2.7 million to $562.0 million year-over-year, while net income declined to $31.7 million from $34.0 million in 2021. For the full year, total revenue rose by $9.1 million to $2,223.2 million, but net income significantly dropped to $118.6 million from $209.1 million in 2021. The company provided 2023 guidance for adjusted net service revenue between $2.244 billion and $2.274 billion and adjusted EBITDA of $230 million to $240 million. Additionally, a divestiture of the personal care line was announced.
Amedisys, Inc. (NASDAQ: AMED) announced a stock repurchase program authorized by its Board of Directors, allowing the company to buy back up to $100 million of its common stock by December 31, 2023. Acting COO and CFO Scott Ginn emphasized the company's solid cash flow and low leverage as reasons for this strategic move, which will complement ongoing efforts in accretive acquisitions in Home Health and Hospice sectors. The repurchases will vary based on market conditions and can be executed through several methods, including open market purchases and private negotiations.
Amedisys, a leader in home health and hospice services, will announce its financial results for the fourth quarter and full year ending December 31, 2022, on February 15, 2023. The investor conference call is scheduled for February 16, 2023, at 11:00 a.m. ET. Callers can join via toll-free (877) 524-8416 or (412) 902-1028. A replay will be available until March 16, 2023. Amedisys provides personalized care through a network of over 532 care centers, catering to more than 465,000 patients annually. Founded in 1982, the company employs roughly 20,000 staff nationwide.
Amedisys, a prominent provider of home health and hospice services, will be presenting at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023, at 8:15 p.m. ET. CEO Paul B. Kusserow will represent the company during this event, which is pivotal for stakeholders and investors. Interested parties can access the live webcast of Amedisys’ presentation by visiting their investor relations website. Amedisys specializes in personalized care services across various healthcare settings and serves over 445,000 patients annually.
Amedisys, Inc. (NASDAQ: AMED) has been recognized as one of the top home health and hospice companies by Computerworld in its 2023 Best Places to Work in IT ranking, placing 34th among large organizations. This accolade highlights Amedisys's commitment to employee engagement through excellent compensation, training, and technology access. The rankings are determined through a comprehensive survey of IT professionals and company offerings, underscoring the company’s dedication to creating a supportive work environment for its IT staff.
Amedisys has finalized a joint venture with the University of Arkansas for Medical Sciences (UAMS) to enhance home health services in Searcy and Little Rock, Arkansas. This collaboration offers a range of clinical services under the UAMS Health Comprehensive Care at Home program, including Recovery, Rehabilitation, and Palliative Care. Amedisys now operates 353 care centers across 35 states with approximately 70,000 patients daily. The company's commitment to quality is reflected in its 4.44 QPC Star score and recognition as a top workplace in healthcare.
FAQ
What is the current stock price of Amedisys (AMED)?
What is the market cap of Amedisys (AMED)?
What services does Amedisys Inc. provide?
Where is Amedisys Inc. headquartered?
How many employees does Amedisys have?
What is the scope of Amedisys's operations?
How many patients does Amedisys serve annually?
What recent merger has Amedisys entered into?
What recent technological advancement has Amedisys incorporated?
What was Amedisys's net service revenue for Q1 2024?
How does Amedisys coordinate patient care?
What was the Personal Care segment of Amedisys?
